Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers
Sarang K Yoon, Kurt T. Hegmann, Matthew S. Thiese, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 19, pp. 1855-1857
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529)
Hassen Mohammed, Dan Duy Pham-Tran, Zi Yi Michelle Yeoh, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 224-224
Open Access | Times Cited: 34
A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines
Feargal J. Ryan, Todd S. Norton, Conor McCafferty, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 3, pp. 100971-100971
Open Access | Times Cited: 26
A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines
Xiao‐Feng He, Jiao Su, Yunan Ma, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 35
Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2
Feyza Gül Özbay Kurt, Alisa Lepper, Catharina Gerhards, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 33
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in Brazil
Érique José Farias Peixoto de Miranda, Rodrigo T. Calado, Fernanda Castro Boulos, et al.
Vaccine (2025) Vol. 52, pp. 126680-126680
Closed Access
Protection of vaccination versus hybrid immunity against infection with COVID-19 Omicron variants among Health-Care Workers
Fotinie Ntziora, Evangelia Georgia Kostaki, Αmalia Karapanou, et al.
Vaccine (2022) Vol. 40, Iss. 50, pp. 7195-7200
Open Access | Times Cited: 23
Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland—A multicentre cohort study
Baharak Babouee Flury, Sabine Güsewell, Thomas Egger, et al.
PLoS Medicine (2022) Vol. 19, Iss. 11, pp. e1004125-e1004125
Open Access | Times Cited: 23
Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong
Runhong Zhou, Na Liu, Xin Li, et al.
The Lancet Regional Health - Western Pacific (2022) Vol. 32, pp. 100660-100660
Open Access | Times Cited: 23
Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis
Obaidur Rahman, Taro Kamigaki, Moe Moe Thandar, et al.
BMJ Open (2023) Vol. 13, Iss. 12, pp. e076892-e076892
Open Access | Times Cited: 15
Risk Factors for Reinfection with SARS-CoV-2 Omicron Variant among Previously Infected Frontline Workers
Katherine Ellingson, James Hollister, Cynthia Porter, et al.
Emerging infectious diseases (2023) Vol. 29, Iss. 3, pp. 599-604
Open Access | Times Cited: 13
Effectiveness of Booster Doses of Monovalent mRNA COVID-19 Vaccine Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children, Adolescents, and Adults During Omicron Subvariant BA.2/BA.2.12.1 and BA.4/BA.5 Predominant Periods
Allison Avrich Ciesla, Ryan E. Wiegand, Zachary Smith, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 5
Open Access | Times Cited: 10
Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy
Hope R. Lapointe, Francis Mwimanzi, Peter K. Cheung, et al.
AIDS (2022) Vol. 37, Iss. 5, pp. 709-721
Open Access | Times Cited: 18
Effectiveness of mRNA Booster Vaccination Against Mild, Moderate, and Severe COVID-19 Caused by the Omicron Variant in a Large, Population-Based, Norwegian Cohort
Ida Laake, Siri N. Skodvin, Kristine Blix, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 11, pp. 1924-1933
Open Access | Times Cited: 16
Effectiveness of Messenger RNA–based Vaccines During the Emergence of the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant
Aditya Sharma, Gina Oda, Mark Holodniy
Clinical Infectious Diseases (2022) Vol. 75, Iss. 12, pp. 2186-2192
Open Access | Times Cited: 15
Effectiveness of mRNA vaccine against Omicron-related infections in the real world: A systematic review and meta-analysis
Kaixin Guo, Peng Ni, Shuailei Chang, et al.
American Journal of Infection Control (2023) Vol. 51, Iss. 9, pp. 1049-1055
Closed Access | Times Cited: 7
Humoral and cell-mediated immune responses in HIV-vertically infected young patients after three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine
Claudia Vanetti, Marta Stracuzzi, Elisa Crivellaro, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 2
Incidence of SARS-CoV-2 Infection Among European Healthcare Workers and Effectiveness of the First Booster COVID-19 Vaccine, VEBIS HCW Observational Cohort Study, May 2021–May 2023
Camelia Savulescu, Albert Prats‐Uribe, Kim Brolin, et al.
Vaccines (2024) Vol. 12, Iss. 11, pp. 1295-1295
Open Access | Times Cited: 2
Humoral immune responses against SARS-CoV-2 Spike variants after mRNA vaccination in solid organ transplant recipients
Alexandra Tauzin, Guillaume Beaudoin-Bussières, Shang Yu Gong, et al.
iScience (2022) Vol. 25, Iss. 9, pp. 104990-104990
Open Access | Times Cited: 11
Humoral Responses in the Omicron Era Following 3-Dose SARS-CoV-2 Vaccine Series in Kidney Transplant Recipients
Caitríona M. McEvoy, Queenie Hu, Kento T. Abe, et al.
Transplantation Direct (2022) Vol. 9, Iss. 1, pp. e1401-e1401
Open Access | Times Cited: 11
Effectiveness of a Messenger RNA Vaccine Booster Dose Against Coronavirus Disease 2019 Among US Healthcare Personnel, October 2021–July 2022
Ian D. Plumb, Nicholas M. Mohr, Melissa Hagen, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 10
Open Access | Times Cited: 6
BNT162b2 versus mRNA-1273 Third Dose COVID-19 Vaccine in Patients with CKD and Maintenance Dialysis Patients
Kevin Yau, Paul Tam, Christopher T. Chan, et al.
Clinical Journal of the American Society of Nephrology (2023) Vol. 19, Iss. 1, pp. 85-97
Open Access | Times Cited: 6
Approaching COVID‐19 with epidemiological genomic surveillance and the sustainability of biodiversity informatics in Africa
Abdullahi Tunde Aborode, Helen Huang, Wireko Andrew Awuah, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Open Access | Times Cited: 9
Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination
Hope R. Lapointe, Francis Mwimanzi, Peter K. Cheung, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 8
Humoral responses to wild type and ancient BA.1 SARS-CoV-2 variant after heterologous priming vaccination with ChAdOx1 nCoV-19 and BNT162b2 booster dose
Giuseppina Sanna, Alessandra Marongiu, Davide Firinu, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Evidence of the Efficacy and the Effectiveness of First Generation COVID-19 Vaccines in Clinical Trials and Real-world Studies
Jingxin Li, Zhuopei Li, Yawen Zhu, et al.
Zoonoses (2022) Vol. 2, Iss. 1
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top